Table 1 Relationship between clinical features and MYEF2 expression in patients with liver cancer from The Cancer Genome Atlas database
From: Expression and function of myelin expression factor 2 in hepatocellular carcinoma
Clinicopathologic features | MYEF2 expression | P value | |
|---|---|---|---|
Low | High | ||
Gender | 0.020 | ||
Male | 194 (71.1%) | 59 (58.4%) | |
Female | 79 (28.9%) | 42 (41.6%) | |
Age (years) | 61 (52–69) | 61 (51–69) | 0.784 |
Tumor stage | 0.004 | ||
I | 138 (54.1%) | 35 (36.8%) | |
II–IV | 117 (45.9%) | 60 (63.2%) | |
Degree of differentiation | 0.001 | ||
G1–G2 | 183 (68.0%) | 50 (50.0%) | |
G3–G4 | 86 (32.0%) | 50 (50.0%) | |
Pathologic Ta | 0.006 | ||
T1 | 145 (53.7%) | 38 (37.6%) | |
T2–T4 | 125 (46.3%) | 63 (62.4%) | |
Distant metastasis | 0.146 | ||
No | 190 (69.6%) | 78 (77.2%) | |
Yes | 83 (30.4%) | 23 (22.8%) | |
AFP (ug/L) | 12 (4.00–144.25) | 24 (3.75–1928.50) | 0.206 |
TB (mg/dl) | 1.2 (1.10–1.30) | 1.2 (1.20–1.30) | 0.277 |
Alb (g/dl) | 4.0 (3.50–4.30) | 4.1 (3.48–4.33) | 0.662 |
Cre (mg/dl) | 0.9 (0.70–1.10) | 1.0 (0.80–1.10) | 0.260 |
PT (s) | 1.1 (1.00–9.45) | 1.1 (0.95–9.00) | 0.148 |
PLT (109/L) | 209 (158.00–303.00) | 213 (162.75–285.50) | 0.971 |
Vascular invasion | 0.063 | ||
No | 160 (68.4%) | 48 (57.1%) | |
Yes | 74 (31.6%) | 36 (42.9%) | |